Business Standard

US pipeline to keep pharma major Lupin's revenues on healthy trajectory

The stock of pharma major Lupin is up 14 per cent over the last eight trading sessions and is trading at Rs 1,406 a share. The gains are on expectations that margins will improve

Lupin Pharma
Premium

Lupin Pharma

Ram Prasad Sahu

Listen to This Article

The stock of pharma major Lupin is up 14 per cent over the last eight trading sessions and is trading at Rs 1,406 apiece. The gains are on expectations that margins will improve on the back of limited competition launches in the US and strong growth in the domestic market.

Given the triggers, some brokerages have increased their earnings per share estimates sharply, with the quantum rising the most in FY2026.

A key trigger for the stock is the launch of the generic version of Spiriva used in the treatment of chronic obstructive pulmonary disorder.

The company got the approval

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 03 2024 | 7:48 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com